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The Association between MC1R Genotype and BRAF
Mutation Status in Cutaneous Melanoma: Findings
from an Australian Population
Elke Hacker1, Nicholas K. Hayward1, Troy Dumenil1, Michael R. James1, and David C. Whiteman1
There is increasing epidemiological and molecular evidence that cutaneous melanomas arise through multiple
causal pathways. The purpose of this study was to explore the relationship between germline and somatic
mutations in a population-based series of melanoma patients to reshape and refine the divergent pathway
model for melanoma. Melanomas collected from 123 Australian patients were analyzed for melanocortin-1
receptor (MC1R) variants and mutations in the BRAF and NRAS genes. Detailed phenotypic and sun exposure
data were systematically collected from all patients. We found that BRAF-mutant melanomas were significantly
more likely from younger patients and those with high nevus counts, and were more likely in melanomas with
adjacent neval remnants. Conversely, BRAF-mutant melanomas were significantly less likely in people with high
levels of lifetime sun exposure. We observed no association between germline MC1R status and somatic BRAF
mutations in melanomas from this population. BRAF-mutant melanomas have different origins from other
cutaneous melanomas. These data support the divergent pathways hypothesis for melanoma, which may
require a reappraisal of targeted cancer prevention activities.
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INTRODUCTION
Cutaneous melanoma is a common form of cancer arising
from the pigment cells of the skin. Risk factors for melanoma
include large numbers of melanocytic nevi, fair skin, and
sunlight exposure (Siskind et al., 2005). Although solar
ultraviolet radiation is the principal environmental risk factor
for these cancers, there is increasing evidence that the effect
of sunlight on pigment cells is not the same for all people.
Epidemiological data support the concept that melanomas
may develop through one of several pathways. Increasingly,
it seems that the molecular profile (particularly for oncogenes
BRAF and NRAS) of cutaneous melanomas reflects these
causal pathways, typified by different patterns of associations
with host and environmental risk factors (Whiteman et al.,
2006, 2003; Curtin et al., 2005; Thomas et al., 2007). For
example, a recent study suggested that melanomas occurring
in younger people with high early-life ambient solar
ultraviolet radiation exposure have a high frequency of BRAF
mutation, whereas melanomas arising in people with high
levels of lifetime solar ultraviolet radiation exposure are
associated with NRAS mutations (Thomas et al., 2007).
The melanocortin-1 receptor (MC1R) gene is a key
determinant of human pigmentation and is highly poly-
morphic with specific variants linked to red hair and
melanoma risk (Palmer et al., 2000; Sturm et al., 2003).
Recently, a synergistic relationship between germline MC1R
variants and somatic BRAF mutations was suggested (Landi
et al., 2006), whereby MC1R variant genotypes conferred a
significantly increased risk of developing BRAF-mutant
melanoma in skin not damaged by sunlight. Recent work
by Fargnoli et al. (2008) further examined the role ofMC1R in
the Italian population and found that patients with MC1R
variants had a higher risk of carrying BRAF mutations in
tumors from chronically sun-exposed sites (odds ratio (OR)
13.9, 95% confidence interval (CI)¼ 1.5–133.3) than inter-
mittently sun-exposed sites (OR 3.4, 95% CI¼ 0.8–14.0),
although this was not significantly different. They reported
increased risks for BRAF-mutant melanoma associated with
variants of MC1R, not only for R variants, but also for r.
Here, we explore the relationship between germline
MC1R status and somatic BRAF mutations in melanomas
from a susceptible population exposed to very high levels of
ambient solar ultraviolet radiation.
RESULTS
Participant characteristics
For this analysis (n¼ 123 patients), mean age at diagnosis was
56.4 years and 48% of patients were females. The percen-
tages of histological subtypes were 62% superficial spreading
melanoma (SSM), 1.6% nodular melanoma (NM), 28%
lentigo maligna melanoma (LMM), and 8.9% unclassified
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melanoma. No acral lentiginous melanoma, spitzoid, or
nevoid lesions were included in this study. Tumors were
generally thin; 85% of the lesions were Clark level I or II, and
74% had Breslow thickness o0.75mm.
BRAF and NRAS mutational frequencies
Mutually exclusive BRAF-mutant and NRAS-mutant tumors
occurred at frequencies of 31.5% and 3%, respectively.
Detection of mutations was based on cutoffs imposed using
DNA from whole blood buffy coat as wild-type controls
(Supplementary Figure S1) and previous studies that have
shown the sensitivity of the Sequenom MassArray platform
(Sequenom Inc., San Diego, CA) to detect mutant alleles as low
as 1.5–3% of the analyzed sample (Vivante et al., 2007). Owing
to the low number of tumors with NRAS mutations, no further
statistical analysis was carried out using these samples.
Clinical and pathological characteristics of BRAF-mutant
lesions
Overall, the mean age at diagnosis for patients carrying a
BRAF V600 mutation was 47.6 years compared with 60.8
years for wild-type cases (t-test Po0.001) (Table 1), and
similar patterns were observed within the pre-specified age
groups (stratumo50 years: mean age BRAF V600 35.4 years
vs wild-type 42.9 years; stratum 50þ years mean age BRAF
V600 58.6 years vs wild-type 66.5 years). There was no
association between gender and BRAF V600 mutation. The
prevalence of BRAF V600 mutations differed by histological
subtype, with only 12% of LMM carrying BRAF mutations
compared with 45% of SSM and 50% of NM (Fisher’s Exact
P¼0.001). Although 21% of in situ melanomas carried BRAF
V600 mutations compared with 50% of invasive lesions (w2
P¼0.02), we found no evidence that the prevalence of BRAF
Table 1. Clinical and pathological characteristics of patients and lesions
Characteristic
BRAF V600
mutation n=40
BRAF V600
wild-type n=83
MC1R
(any variant) n=90
MC1R
wild-type1 n=33
MC1R (r/wt
or r/r) n=33
MC1R (any R
allele) n=57
Age at diagnosis (years)
Mean+SD, years 47.6+14.1 60.8+13.4 56.1+14.7 57.3+15.8 56.3+15.8 56+14.2
Gender, n (%)
Male 17 (27) 47 (73) 49 (77) 15 (23) 18 (37) 31 (63)
Female 23 (39) 36 (61) 41 (69) 18 (31) 15 (37) 26 (63)
Histological subtype
SSM 34 (45) 42 (55) 56 (74) 20 (26) 22 (39) 34 (61)
NM 1 (50) 1 (50) 1 (50) 1 (50) 0 (0) 1 (100)
LMM 4 (12) 30 (88) 24 (71) 10 (29) 8 (33) 16 (67)
Not stated 1 (9) 10 (91) 9 (82) 2 (18) 3 (33) 6 (67)
Pathological classification
In situ 12 (21) 45 (79) 39 (68) 18 (32) 14 (36) 25 (64)
Invasive 28 (42) 38 (58) 51 (77) 15 (23) 19 (37) 32 (63)
Clark level
1 13 (20) 52 (80) 46 (71) 19 (29) 15 (33) 31 (67)
2 18 (46) 21 (54) 29 (74) 10 (26) 11 (38) 18 (62)
X3 8 (50) 8 (50) 12 (75) 4 (25) 7 (58) 5 (42)
Not stated 1 (33) 2 (67) 3 (100) 0 (0) 0 (0) 3 (100)
Breslow thickness
o0.75mm 19 (46) 22 (54) 30 (73) 11 (27) 12 (40) 18 (60)
X0.75mm 7 (50) 7 (50) 11 (79) 3 (21) 6 (55) 5 (45)
Not stated 14 (21) 54 (79) 49 (72) 19 (28) 15 (31) 34 (69)
MC1R, melanocortin-1 receptor.
1Wild-type here denotes an MC1R allele that does not carry any of the eight variants we measured (listed in Table 4).
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V600 mutation increased further with increasing depth of
invasion.
Phenotypic and environmental factors associated with BRAF
mutations
Compared with patients who had 0–15 nevi, those with 16–60
nevi were 10-fold more likely to have BRAF V600 mutant
melanoma and patients with 460 nevi had similarly
increased risks of harboring a mutation (Table 2). Further-
more, melanomas with evidence of adjacent neval remnants
were more likely to have a BRAF V600 mutation (OR 2.7,
95% CI¼1.2–6.2). The ability to develop a tan was also
associated with tumors that carried BRAF V600 mutations
(OR 4.3, 95% CI¼ 1.8–10.4). Freckling, and hair and eye
color were not significantly associated with BRAF V600
mutational status.
We found no association between anatomic site (head and
neck vs trunk and limbs) and BRAF V600 mutation; however,
we found that BRAF V600 mutant melanomas were
statistically significantly less likely to occur in people in the
highest groups of cumulative sun exposure or actinic
keratosis counts (Table 2). Similarly, BRAF V600 mutant
melanomas were less common among people who reported
large numbers of sunburns as adults, although this was not
statistically significant.
To assess which of these phenotypic and environmental
factors was most predictive of BRAF V600 mutation status,
we fitted multivariable logistic regression models using a
variety of supervised algorithms. Regardless of the approach
to model-fitting (forwards, backwards, and stepwise), the final
model included terms only for total nevus count and the
presence of contiguous neval remnants (in addition to the
sampling variables, age group, and sex) as the best predictors
of BRAF V600 mutation status for melanoma (Table 3).
We repeated all of the analyses restricted only to the
patients with invasive melanomas, and found essentially
similar patterns to those reported above, albeit with reduced
precision (Supplementary Table S1).
Frequency of MC1R variants
In all, 74.5% of melanoma patients carried one of the eight
common MC1R variants, consistent with previous reports in
this population. The estimated allele frequency of measured
variants in this population is presented in Table 4. There was
no association of MC1R variants with gender, histological
subtype, and invasive classification.
Phenotypic and environmental factors associated with MC1R
variants
Of a number of phenotypic characteristics for which we
sought associations with MC1R (Supplementary Table S2),
the only characteristic statistically significantly associated
with MC1R status was freckling density on both the face and
arms (few facial freckles OR 2.1, 95% CI¼ 0.8–5.5; many
facial freckles OR 9.8, 95% CI¼2.4–39.4; P¼0.03).
Although not statistically significant owing to the small
numbers, red hair was only observed in patients carrying
MC1R variants. There was no increase in the number of total
body nevi or actinic keratosis in patients carrying MC1R
variants, and neither was there any association with sun
exposure (Supplementary Table S2).
BRAF and MC1R
There was no association between germline MC1R variants
and somatic BRAF V600 mutations in tumor samples
(Table 5). Lesions were categorized into intermittently and
chronically sun-exposed body sites but no difference in the
rates of BRAF V600 mutations was observed. As we found a
lower incidence of BRAF V600 mutations in LMM lesions, we
repeated the analysis excluding this sub-type but still found
no observed difference in the prevalence of BRAF V600
mutations among patients carrying MC1R variants (Supple-
mentary Table S3). Owing to the age structure of our cases,
we further investigated the relationships between MC1R and
somatic BRAF V600 mutations overall, and within the broad
strata of actinic keratosis and sun exposure history (Table 5).
However, there was no observed difference in the prevalence
of BRAF V600 mutations among patients carrying MC1R
variants compared with patients with wild-type MC1R. We
also excluded the possibility of the LMM subtype confound-
ing the data by excluding them (Supplementary Table S3).
We further analyzed the relationship between germline
MC1R variants and somatic BRAF mutations restricted only
to patients with invasive melanomas and found no associa-
tion between the prevalence of BRAF V600 mutations among
patients carrying MC1R variants compared with patients with
wild-type MC1R (Supplementary Table S3).
DISCUSSION
We have analyzed melanoma samples from an Australian
population to further explore the ‘‘divergent pathway model’’
for melanoma. This model proposes at least two different
causal pathways to melanoma development, one arm
pertaining to host susceptibility and nevus growth, and another
arm associated with chronic sun exposure. Our results accord
with this model, as we found that melanomas with and
without BRAF V600 mutations displayed significantly different
associations with a range of phenotypic, histological, and
environmental factors. We found that melanomas harboring
BRAF V600 mutations were more likely among younger
patients and those with high nevus counts, and were more
likely to occur in melanomas with adjacent neval remnants.
Melanomas with BRAF V600 mutations were less likely to
occur in people with evidence of high levels of lifetime sun
exposure, such as self-reported sun exposure history and nurse
counts of actinic keratosis. In keeping with this observation,
melanomas of the lentigo maligna subtype exhibited a lower
frequency of BRAF V600 mutations. Patients with tumors
carrying BRAF V600 mutations had the ability to develop a
tan, suggesting intact pigmentation pathways. Although BRAF
V600 mutant melanomas were more likely to occur in
younger people, it was notable that such lesions were more
likely to be invasive compared with wild-type melanomas. It
has been suggested that BRAF V600 mutations are induced in
melanocytes as a result of childhood sun exposure (Thomas
et al., 2007). Presumably, a proportion of these transformed
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cells progress to melanoma, accounting for the younger mean
age of diagnosis.
Only a few studies to date have examined determinants for
BRAF V600 mutations in melanoma (Landi et al., 2006;
Thomas et al., 2007; Fargnoli et al., 2008). Our findings are in
substantial agreement with those of a study conducted in
North Carolina by Thomas et al. (2007), although we
Table 2. Association between phenotypic factors and
BRAF V600 mutations in cutaneous melanoma
Characteristic
BRAF V600
mutation
n=40
BRAF V600
wild-type
n=83
OR
(95% CI)1
Total nevus count
0–15 2 (6) 33 (94) 1.0 (ref)
16–60 19 (41) 27 (59) 10.9 (2.3–51.6)
460 17 (46) 20 (54) 11.9 (2.3–61.2)
Missing 2 3
Contiguous neval remnants
No 17 (22) 59 (78) 1.0 (ref)
Yes 23 (49) 24 (51) 2.7 (1.2–6.2)
Propensity to tan
Light or no tan 13 (21) 48 (79) 1.0 (ref)
Mod/Deep tan 27 (45) 33 (55) 4.3 (1.8–10.4)
Missing 2
Freckles face
None 14 (36) 25 (64) 1.0 (ref)
Few 14 (31) 31 (69) 0.7 (0.3–1.8)
Many 12 (32) 26 (68) 0.6 (0.2–1.6)
Missing 1
Eye color
Blue and green 23 (33) 47 (67) 1.0 (ref)
Black or brown 15 (31) 33 (69) 0.8 (0.3–1.9)
Missing 2 3
Hair color
Black/brown 30 (33) 60 (67) 1.0 (ref)
Blondes 9 (39) 14 (61) 1.1 (0.4–2.9)
Red 1 (11) 8 (89) 0.2 (0.0–1.9)
Missing 1
Tumor site
Trunk and limbs 13 (30) 36 (70) 1.0 (ref)
Head and neck 27 (35) 47 (65) 1.4 (0.6–3.1)
Ambient sun exposure
Low 17 (44) 22 (56) 1.0 (ref)
Medium 15 (37) 25 (63) 1.0 (0.4–2.7)
High 8 (19) 35 (81) 0.5 (0.2–1.4)
Missing 1
Table 2. Continued
Characteristic
BRAF V600
mutation
n=40
BRAF V600
wild-type
n=83
OR
(95% CI)1
Total number of solar
keratosis
None 22 (51) 21 (49) 1.0 (ref)
1–20 12 (34) 23 (66) 0.6 (0.2–1.7)
420 4 (10) 36 (90) 0.1 (0.0–0.5)
Missing 2 3
Propensity to sun burn
Rare/never/some 13 (38) 21 (62) 1.0 (ref)
Mostly burn 18 (42) 25 (58) 0.9 (0.3–2.5)
Always burn 9 (20) 35 (80) 0.3 (0.1–0.9)
Missing 2
Number of sun burns
since school
Never 5 (56) 4 (44) 1.0 (ref)
1–5 16 (30) 37 (70) 0.3 (0.1–1.4)
6–20 17 (36) 30 (64) 0.4 (0.1–2.0)
420 2 (17) 10 (83) 0.2 (0.0–1.4)
Missing 2
1Odds ratio (OR) and 95% confidence interval (CI), adjusted for age
stratum (o50, 50+), and sex.
Table 3. Association between risk factors and BRAF
V600 mutations in cutaneous melanoma: stepwise
logistic regression model
Characteristic OR (95% CI)1
Total nevus count
0–15 1.0 (ref)
16–60 11.8 (2.4–57.7)
460 9.7 (1.8–52.1)
Contiguous neval remnants
No 1.0 (ref)
Yes 3.1 (1.2–8.1)
1Odds ratio (OR) and 95% confidence interval (CI), adjusted for age
stratum (o50, 50+), sex, and all other terms in table.
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observed no association between anatomic site and pre-
valence of BRAF V600 mutations. It is important to note that
the lack of association here most likely reflects the sampling
strategy used in the parent study from which these samples
were derived (Whiteman et al., 2003). Patients in the parent
study were frequency-sampled within strata of age, sex, and
anatomic site to ensure similar numbers of younger and older
patients for each body site. In our sample, the mean age of
patients with melanoma of the head and neck was actually
younger (55 years) than that of patients with melanoma of the
trunk (58 years). This was entirely because of the sampling, as
our previous studies in the same population have shown that
on average, patients with head and neck melanomas are
significantly older than those with melanomas of the trunk
(Siskind et al., 2005). Our findings differ from that of Fargnoli
et al., for which the published data (their Table 2) suggest no
association between nevus count and BRAF mutation when
nevus count was dichotomized at the median.
We sought to explore the biological differences between
in situ and invasive melanomas by reanalyzing the data set
restricted only to invasive melanomas. The findings are
essentially unchanged, although with the reduced sample
size, the precision of risk estimates is less than the originally
reported findings (Supplementary Table S1). We sought to
explore the effects of age and anatomical site in melanoma
causation by intentionally sampling patients from within pre-
defined strata. One consequence of this is that in Queensland
at least, younger patients with melanocytic lesions tend to
present for medical care early, especially for facial melano-
mas. As a result, most melanomas among young people are
thin lesions, particularly on the head and neck.
Importantly, our findings differ from the studies by Landi
and colleagues (Landi et al., 2006; Fargnoli et al., 2008),
which were based on sequenced MC1R and BRAF genes and
Table 4. Estimated allele frequency of MC1R variants
Variant allele
Frequency
(%) in
tumors
Frequency (%) in
South East
Queensland
population
(Duffy et al., 2004)
Frequency (%) in
melanoma patients
by direct sequencing
(Kanetsky et al.,
2006)
R142H 1.5 0.4 1.0
V60L 12.3 12.2 13.3
D84E 1.2 1.2 1.8
R151C 15.0 11.0 13.2
R160W 6.9 7.0 9.8
D294H 2.7 2.7 2.8
V92M 10.8 9.7 10.0
R163Q 5 4.7 4.2
All other
variants
Not done 0.9 4.0
r 28.1 26.6 27.5
R 27.3 22.3 28.6
MC1R, melanocortin-1 receptor.
r=V60L, V92M, R163Q.
R=R142H, D84E, R151C, R160W, D294H.
Table 5. The lack of association between MC1R and
BRAF
BRAF V600
MC1R WT Mutant OR (95% CI)1
All lesions
WT/WT 21 (64) 12 (36) Ref
Any variant 62 (69) 28 (31) 0.72 (0.28–1.82)
Total 83 40
Intermittent sun exposed lesions (Trunk and upper limbs and lower limbs)
WT/WT 7 (64) 4 (36) Ref
Any variant 28 (76) 9 (24) 0.4 (0.07–2.14)
Total 35 13
Chronic sun exposed lesions (Head and neck)
WT/WT 13 (62) 8 (38) Ref
Any variant 33 (63) 19 (37) 0.98 (0.31–2.93)
Total 46 27 —
Lower category of sun exposure (0–5 actinic keratosis)
WT/WT 4 (40) 6 (60) Ref
Any variant 17 (52) 16 (48) 0.68 (0.21–2.22)
Total 21 22 —
High category of sun exposure (6+ actinic keratosis)
WT/WT 16 (73) 6 (27) Ref
Any variant 43 (81) 10 (19) 0.69 (0.14–3.31)
Total 59 16 —
Low sun exposure (low exposure history)
WT/WT 9 (47) 10 (53) Ref
Any variant 38 (63) 22 (37) 0.76 (0.19–2.97)
Total 47 32 —
High sun exposure (High exposure history)
WT/WT 12 (86) 2 (14) Ref
Any variant 23 (79) 6 (21) 0.77 (0.21–2.84)
Total 35 8 —
CI, confidence interval; MC1R, melanocortin-1 receptor; OR, odds ratio;
WT, wild-type.
1Odds ratio and 95% confidence interval, adjusted for age and sex.
There were two lesions missing site location information, five lesions
missing actinic keratosis information, and one lesion missing sun exposure
history.
WT/WT here denotes an MC1R allele that does not carry any of the eight
variants we measured (listed in Table 4).
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were restricted only to invasive melanomas. We observed no
association between germline MC1R status and the preva-
lence of somatic BRAF V600 mutations in melanomas, even
after classifying lesions into intermittent and chronic sun-
exposed sites. We further investigated the relationships
between MC1R and BRAF V600 mutations using the number
of actinic keratosis and self-reported sun exposure history as
proxies for total sun exposure; however, we found no
evidence of any difference in the prevalence of BRAF V600
mutation by MC1R status. It is possible that the discordant
study findings reflect underlying differences in the popula-
tions, although the small sample sizes for each study mean
that chance cannot be excluded. Clearly, further studies of
substantially larger size are warranted to clarify the possible
biological relationship between germline MC1R status and
somatic BRAF mutations.
The strengths of our study include the population-based
sampling frame and the detailed epidemiological data
(including nurse counts of nevi and actinic keratosis blind
to genotype status) accompanying the tumor specimens. In
particular, we intentionally oversampled younger patients
with melanoma to ensure that we could account for possible
age-specific differences in associations between likely causal
factors and site of melanoma. The prevalence of somatic
BRAF V600 mutation-positive samples (31.5%) was consis-
tent with previous reports (Thomas et al., 2007), and the
distribution of MC1R variants was very similar to earlier
reports from Queensland (Duffy et al., 2004).
A limitation of this study was the restricted number of
samples for analysis, because of the use of tissue samples for
earlier immunohistochemical investigations (Lee et al., 2006;
Richmond-Sinclair et al., 2008). To assess possible selection
bias, we compared the prevalence of phenotypic (including
skin type, hair and eye color, freckling density, and counts of
nevi and actinic keratosis) and histological (contiguous neval
remnants, thickness, and anatomic site) characteristics as
well as the age and sex among those participants with tumor
blocks available for analysis and those without. The distribu-
tions were similar in each group of patients (data not shown).
A further limitation is that we did not carry out full
sequencing of the entire MC1R gene. However, our distribu-
tion of variants (Table 4) is very similar to the largest
sequencing effort thus far completed in Caucasian popula-
tions (Kanetsky et al, 2006). The MC1R variants genotyped in
this study comprise over 93% of the non-synonymous
changes observed in the Kanetsky study, which analyzed a
far more ethnically diverse sample than our study (USA, Italy,
and Australia). Therefore, we do not believe that the rare
MC1R variants not covered in our investigation would
markedly affect our risk estimates; assessment in a large
population-based sample is necessary to conclusively address
this issue.
In light of these findings, we have refined and extended the
divergent molecular pathway model by explicitly incorporat-
ing mutational events as well as additional environmental and
phenotypic data (Figure 1). The initiation event in this model
is early-life sun exposure, which has previously been shown
using migrant studies to hold the greatest risk for developing
melanoma later in life (Whiteman et al., 2001). Work by
Bauer et al. (2007) has shown that congenital nevi, which
develop independently of sun exposure, lack BRAF V600
mutations, whereas acquired nevi are associated with sun
exposure in early life (English et al., 2006) and commonly
harbor BRAF V600 mutations (Pollock et al., 2003).
Several studies have speculated that host factors may
underlie susceptibility for melanocyte proliferation and nevus
formation. Work by Bataille et al. (2007) explored telomere
length in white blood cells as a possible predictor of nevus
counts. Participants with high nevus counts exhibited longer
telomeres, and it has been inferred that such individuals may
have increased cellular replicative potential. It is presumed
that this is not just limited to melanocytes. Genome-wide
Normal
melanocyte
Initiated
melanocyte
Individuals with
few nevi
Sun exposure
Individuals with many
actinic keratosis
Non-BRAF mutant
melanomas and
frequently LMM
subtype
BRAF mutant
melanomas mostly on
body sites adjacent to
nevi
Individuals with MANY nevi
80% BRAF mutant
AGE
Childhood Adolescence Adulthood
Sun exposure
Individuals with FEW
actinic keratosis
Sun exposure Sun exposure
Sun exposure
Figure 1. The divergent molecular pathway model of melanoma development incorporates molecular, environmental, and phenotypic data.
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linkage studies for nevus counts have identified several
regions of linkage on chromosomes 2, 5, 8, 9, and 17. Of
particular interest was the association of the CDKN2A locus
with nevus formation (Falchi et al., 2006; Zhu et al., 2007).
Mutations and loss of p16 (one product encoded by
CDKN2A) are well documented in melanoma, and it appears
that p16 contributes to melanoma pathogenesis through
pathways that escape routine senescence.
In conclusion, our work provides further support for the
divergent pathway hypothesis for melanoma by showing that
BRAF V600 mutant melanomas occur more commonly in
younger individuals and those with high nevus counts, and
occur in melanomas with contiguous neval remnants. These
findings suggest that a subgroup exists within the general
population at risk of BRAF V600 mutant melanoma, and that
these people may be characterized by distinct phenotypic
attributes. Understanding the interacting roles of sunlight,
susceptibility, and BRAF mutation on melanoma develop-
ment is the aim of our continuing research.
MATERIALS AND METHODS
Participants
We compared the prevalence of BRAF and NRAS mutations in
formalin-fixed paraffin-embedded melanoma specimens from 123
patients ascertained from the Queensland Cancer Registry. A
detailed description of participant selection and data collection for
this study has been described previously (Whiteman et al., 2003).
Briefly, eligible patients were residents of greater Brisbane, Australia
(latitude 271S) who were diagnosed with a histologically confirmed
primary cutaneous melanoma between 1 January 1998 and 31
December 1999. Patients were intentionally sampled within
predefined strata of age (o50 years, 450 years) and sex to ensure
similar distributions for these variables in the ensuing epidemiolo-
gical analyses. Those with metastatic melanoma or a previous
diagnosis of melanoma were not eligible. Of 452 eligible patients for
the initial epidemiological study, 387 (86%) completed question-
naires and 328 (73%) provided written informed consent to obtain
specimens of archived melanoma tissue. This analysis was restricted
to 123 patients for whom sufficient material was remaining for
mutation analysis. The age and sex distribution of the 123 patients
who were genotyped for BRAF was the same as for the 264 patients
who were not.
Approval to conduct the study was given by the Human Research
Ethics Committee of the Queensland Institute of Medical Research
and the Queensland Cancer Registry. The declarations of Helsinki
principles were followed and all participants gave their written
consent to take part.
DNA isolation
Hematoxylin and eosin-stained sections of each patient’s melanoma
were assessed for areas of normal and tumor tissue, and the
percentage of tumor cells was recorded. Formalin-fixed, paraffin-
embedded tissue sections were dissected to select areas where
melanoma cells dominated over stromal cells. Sections (20 mm) were
cut from each tumor block and deparaffinized in xylene and washed
twice in absolute ethanol. DNA was isolated using Qiagen DNeasy
Tissue Kit (Qiagen, Strasse, Germany), with additional proteinase K
digestion at 55oC for 48 hours. DNA was extracted from whole
blood buffy coat and melanoma cell lines using Qiagen DNeasy kits
(Qiagen). DNA quantification was determined by spectrophotometry
(Nanodrop, Wilmington, DE) and DNA quality was checked using
2% agarose gels (Amresco, Solon, OH).
MC1R, BRAF, and NRAS genotyping
Genotyping was carried out using the MassArray platform (Seque-
nom Inc.). An optimized multiplex assay of all common and a subset
of rare known variants of MC1R were used as previously described
(Duffy et al., 2004). Only non-synonymous variants or insertions/
deletions in MC1R were considered in this analysis.
BRAF V600 and NRAS Q61 mutations were detected with single
base extension or allele-specific assays, using the iPLEX genotyping
format (Sequenom Inc.) (see Supplementary Table S4 for primer
details). Samples were analyzed in duplicate with genotyping
repeated thrice to confirm mutation status. Melanoma cell lines
previously characterized in (Stark and Hayward, 2007) were used in
this study as positive controls for the MC1R, BRAF, and NRAS
genotyping assays. DNA from whole blood buffy coat was used as
wild-type controls in the BRAF and NRAS genotyping assays
(Supplementary Figure S1). We have examined only the BRAF
V600 mutations; other rare changes such as D594, L597, and L584
were not examined in this study.
Phenotypic characteristics and sun exposure history
Relevant exposure data (including sun exposure history and skin
sensitivity) were collected from study participants through a self-
completed, structured questionnaire as described previously (White-
man et al., 2003). In addition to background information, we asked
participants to report their occupational history (including periods of
study and unemployment) since leaving school. We asked partici-
pants to report how much time they spent outdoors in the sun in
summer on work and non-work days for each period of employment.
Participants were asked to report their nevus burden as a teenager
and the number of previous treatments for keratinocyte cancers (basal
cell carcinomas and squamous cell carcinomas). Finally, a single
trained research nurse who was unaware of the study hypotheses
examined each participant. The nurse recorded hair and eye color,
and counted melanocytic nevi and solar keratoses. Nevi were defined
as pigmented macules or papules of any size and distinguished from
freckles and seborrheic keratoses. Numbers of nevi were counted on
the head and neck, the upper limbs, and the trunk and were classified
according to size as less than 5mm or greater than or equal to 5mm
in diameter by use of a transparent plastic stencil. Freckles were
defined as irregular but sharply demarcated macules, usually small
(o4mm), uniformly pigmented (tan/light brown), and usually
occurring in clusters on exposed body sites. The density of freckling
on the face was categorized on a four-point scale. Solar keratoses,
defined as superficial, rough scaly areas with erythematous back-
ground and ill-defined margins, were counted separately on the
dorsal surfaces of the hands, forearms, and face.
Statistical analysis
We calculated the amount of sun exposure received on working days
(hereafter ‘‘occupational exposure’’) by multiplying the duration of
each employment period (in weeks) by the number of days per week
worked, and the number of hours per day spent outdoors in the sun
on workdays. Ambient recreational exposure was calculated in a
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similar manner using self-reported estimates of sun exposure on non-
work days in each employment period. We summed occupational
and recreational sun exposures across all employment periods after
age 20 years up until age of diagnosis to derive cumulative totals for
each pattern of exposure. Total ambient sun exposure for each
participant was the sum of cumulative occupational and recreational
sun exposure.
We carried out simple cross-tabulations and calculated Pearson’s
w2 and/or Fischer’s exact test (for cells with expected count of less
than 5) as a measure of statistical association. We used multivariable
logistic regression to calculate ORs and 95% CIs as the measure of
association between patient/tumor characteristics and BRAF muta-
tion status (V600 mutant vs V600 wild-type). We included terms for
age stratum (o50 years, 450 years) and sex to control for possible
confounding introduced by the study design. We conducted
supervised model fitting to identify the best model to predict BRAF
V600 mutation status using forward, backward, and stepwise
elimination procedures. P-values less than or equal to 0.05 were
considered as statistically significant and all such tests were two-
sided. All analyses were carried out using the SAS 9.1 statistical
software package (SAS Institute, Cary, NC).
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